- RTI Surgical has acquired Collagen Solutions, expanding its portfolio in regenerative medicine.
- The acquisition enhances RTI’s access to key therapeutic areas, including cardiac, sports medicine, and orthopaedics.
RTI Surgical announced the acquisition of Collagen Solutions, a global supplier of medical-grade collagen and xenograft tissue used in various therapeutic areas such as cardiac, sports medicine, and orthopaedics. The move strengthens RTI’s soft tissue portfolio, following its earlier acquisition of Cook Biotech.
The acquisition allows RTI to further its reach in high-growth medical fields and provides an opportunity to accelerate the development of innovative biomaterials. With a focus on improving patient outcomes, the expanded portfolio enables RTI to collaborate more effectively with customers, particularly in addressing unmet needs in areas such as tissue reconstruction and heart repair.
“Collagen Solutions is an excellent strategic fit for RTI Surgical,” said Olivier Visa, President and CEO of RTI Surgical. “Together, we are building on a significant track record with a combined 50 years of experience in regenerative medicine.”
Collagen Solutions, headquartered in Eden Prairie, Minneapolis, with additional sites in the UK and New Zealand, brings expertise in bovine and porcine collagen. The acquisition, supported by RTI’s main shareholder Montagu, enhances the company’s ability to partner with OEM customers in developing innovative solutions.
The leadership at Collagen Solutions is optimistic about the future under RTI’s guidance. “RTI shares our strong commitment to quality, innovation, and customer care,” said Rick Mulford, CEO of Collagen Solutions.
Overview of outsourcing trends 
